{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:10:59Z","timestamp":1780920659152,"version":"3.54.1"},"reference-count":124,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>Psilocybin, a classic psychedelic compound, has garnered renewed interest as a potential treatment for various psychiatric disorders. This review provides a comprehensive overview of psilocybin's history, recent clinical evidence, ongoing clinical trials, neuroimaging findings, and regulations. Historically used in spiritual and healing rituals, psilocybin was in the early 1970s subjected to strict legal restrictions that stalled research for decades. However, renewed scientific interest began in the 1990s, with studies demonstrating psilocybin's therapeutic potential for psychiatric disorders. Clinical trials have reported therapeutic effects of psilocybin in major depressive disorder (MDD), depressive symptoms associated with life\u2010threatening illnesses, and in some substance use disorders. Moreover, several phase III clinical trials of psilocybin for depression are currently underway, though trial data for obsessive\u2010compulsive disorder and bipolar depression are limited. Short\u2010term side effects are reportedly generally mild and transient, but long\u2010term effects still need further investigation. Neuroimaging research using magnetic resonance imaging and electroencephalography is still limited and focuses mainly on MDD. However, ongoing clinical trials include neuroimaging studies for psychiatric disorders beyond MDD, as well as positron emission tomography studies for MDD. Regulatory frameworks vary internationally. While many countries continue to classify psilocybin as a prohibited substance, use of psilocybin under controlled conditions is now permitted in Switzerland, parts of the United States, Canada, and Australia. Despite encouraging data, challenges remain, including the need for larger, blinded trials, standardized protocols, and clarification of long\u2010term efficacy and safety. Psilocybin represents a novel therapeutic approach in psychiatric treatment, warranting further rigorous scientific and regulatory research.<\/jats:p>","DOI":"10.1111\/pcn.70042","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T10:08:59Z","timestamp":1772964539000},"page":"438-458","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Psilocybin for psychiatric disorders: History, clinical trials, neuroimaging, and regulations"],"prefix":"10.1111","volume":"80","author":[{"given":"Kengo","family":"Yonezawa","sequence":"first","affiliation":[{"name":"Department of Neuropsychiatry Keio University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuko","family":"Hirata","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry Keio University School of Medicine  Tokyo Japan"},{"name":"Division of Drug Informatics Keio University Faculty of Pharmacy  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Takano","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry Keio University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kusudo","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry Keio University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sota","family":"Tomiyama","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry Keio University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry Keio University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouta","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry Keio University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Nutt","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, Department of Brain Sciences Imperial College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0628-7036","authenticated-orcid":false,"given":"Hiroyuki","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry Keio University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8782-0399","authenticated-orcid":false,"given":"Hideaki","family":"Tani","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry Keio University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2017.84"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(16)30065-7"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675512"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/NMD.0000000000000113"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.1979.10472098"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5949.2008.00059.x"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.115.011478"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.12.040"},{"key":"e_1_2_10_10_1","volume-title":"Acid Dreams: The Complete Social History of LSD: The CIA, the Sixties, and beyond","author":"Lee MA","year":"1992"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1994.03950020022002"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-006-0457-5"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.17398"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpsc.2024.01.002"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-022-02876-5"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045125320950567"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-017-4771-x"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2018.01721"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-017-4754-y"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032994"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.788155"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2023.04.105"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.3285"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811211073759"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206443"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01648-7"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2023.01.108"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811231154852"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.14530"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101809"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.01.005"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2023.4685"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.09.133"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2024.115886"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811241287542"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20231063"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2023.535"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2010.116"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675513"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119897615"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.1c00020"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100538"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35010"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35889"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2023.06.006"},{"key":"e_1_2_10_46_1","first-page":"273","article-title":"Prelminary report on the experience with psychosomimetic drugs in the treatment of alcobolism","volume":"10","author":"Rydzy\u0144ski Z","year":"1968","journal-title":"Act. Nerv. Super."},{"key":"e_1_2_10_47_1","first-page":"81","article-title":"Treatment of alcoholism with psychotomimetic drugs. A Follow\u2010Up Study","volume":"20","author":"Rydzy\u0144ski Z","year":"1978","journal-title":"Act. Nerv. Super."},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881114565144"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881114548296"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.3109\/00952990.2016.1170135"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2022.2096"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n1110"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2025.152619"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02455-9"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s43440-023-00539-4"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.13741"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291723001411"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1177\/24705470221115342"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13282-7"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.12.041"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119895520"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2023.04.081"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811221125354"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01744-z"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.02.089"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01706-y"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811231179800"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.118.017160"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-28111-3"},{"key":"e_1_2_10_70_1","unstructured":"21 USC chapter 13 subchapter I: Control and enforcement. 2025. [Cited 27 March 2025.] Available from URL:https:\/\/uscode.house.gov\/view.xhtml?edition=prelim&path=%2Fprelim%40title21%2Fchapter13%2Fsubchapter1."},{"key":"e_1_2_10_71_1","unstructured":"Oregon Health Authority.Oregon psilocybin services: Prevention and wellness: State of Oregon. 2025. [Cited 28 March 2025.] Available from URL:https:\/\/www.oregon.gov\/oha\/PH\/PREVENTIONWELLNESS\/Pages\/Oregon\u2010Psilocybin\u2010Services.aspx."},{"key":"e_1_2_10_72_1","unstructured":"Oregon Health Authority.Oregon psilocybin services \u2013 Access psilocybin services: Prevention and wellness: State of Oregon. 2025. [Cited 28 March 2025.] Available from URL:https:\/\/www.oregon.gov\/oha\/PH\/PREVENTIONWELLNESS\/Pages\/Psilocybin-Access-Psilocybin-Services.aspx."},{"key":"e_1_2_10_73_1","unstructured":"Oregon secretary of state administrative rules 333\u2010333\u20102010. [Cited 8 July 2025.] Available from URL:https:\/\/secure.sos.state.or.us\/oard\/viewSingleRule.action?ruleVrsnRsn=319933."},{"key":"e_1_2_10_74_1","unstructured":"Oregon secretary of state administrative rules 333\u2010333\u20105170. [Cited 18 November 2025.] Available from URL:https:\/\/secure.sos.state.or.us\/oard\/viewSingleRule.action?ruleVrsnRsn=319987."},{"key":"e_1_2_10_75_1","unstructured":"Oregon psilocybin services \u2013 administrative rules. [Cited 28 June 2025.] Available from URL:https:\/\/www.oregon.gov\/oha\/PH\/PREVENTIONWELLNESS\/Pages\/Psilocybin\u2010Administrative\u2010Rules.aspx."},{"key":"e_1_2_10_76_1","unstructured":"Oregon secretary of state administrative rules 333\u2010333\u20103050. [Cited 28 June 2025.] Available from URL:https:\/\/secure.sos.state.or.us\/oard\/viewSingleRule.action?ruleVrsnRsn=319941."},{"key":"e_1_2_10_77_1","unstructured":"Oregon secretary of state administrative rules 333\u2010333\u20103070. [Cited 28 June 2025.] Available from URL:https:\/\/secure.sos.state.or.us\/oard\/viewSingleRule.action?ruleVrsnRsn=319942."},{"key":"e_1_2_10_78_1","unstructured":"Oregon secretary of state administrative rules 333\u2010333\u20105050. 2025. [Cited 4 May 2025.] Available from URL:https:\/\/secure.sos.state.or.us\/oard\/viewSingleRule.action?ruleVrsnRsn=319978."},{"key":"e_1_2_10_79_1","unstructured":"Oregon secretary of state administrative rules 333\u2010333\u20105000. 2025. [Cited 20 June 2025.] Available from URL:https:\/\/secure.sos.state.or.us\/oard\/viewSingleRule.action?ruleVrsnRsn=319975."},{"key":"e_1_2_10_80_1","unstructured":"Oregon secretary of state administrative rules 333\u2010333\u20105040. 2025. [Cited 4 May 2025.] Available from URL:https:\/\/secure.sos.state.or.us\/oard\/viewSingleRule.action?ruleVrsnRsn=319977."},{"key":"e_1_2_10_81_1","unstructured":"Oregon secretary of state administrative rules 333\u2010333\u20105200. [Cited 28 June 2025.] Available from URL:https:\/\/secure.sos.state.or.us\/oard\/viewSingleRule.action?ruleVrsnRsn=319989."},{"key":"e_1_2_10_82_1","unstructured":"Oregon Secretary of State Administrative Rules 333\u2010333\u20105260.2025. [Cited 4 May 2025.] Available from URL:https:\/\/secure.sos.state.or.us\/oard\/viewSingleRule.action?ruleVrsnRsn=309297."},{"key":"e_1_2_10_83_1","unstructured":"Oregon secretary of state administrative rules 333\u2010333\u20104910. [Cited 28 June 2025.] Available from URL:https:\/\/secure.sos.state.or.us\/oard\/viewSingleRule.action?ruleVrsnRsn=319972."},{"key":"e_1_2_10_84_1","unstructured":"Colorado legal resources C.R.S. 18\u201018\u2010203. [Cited 28 June 2025.] Available from URL:https:\/\/advance.lexis.com\/documentpage\/?pdmfid=1000516&crid=11af3cc1\u2010ed2d\u20104c01\u2010b28c\u201040ae01a7e499&config=014FJAAyNGJkY2Y4Zi1mNjgyLTRkN2YtYmE4OS03NTYzNzYzOTg0OGEKAFBvZENhdGFsb2d592qv2Kywlf8caKqYROP5&pddocfullpath=%2fshared%2fdocument%2fstatutes\u2010legislation%2furn%3acontentItem%3a65S8\u20101453\u2010GXF6\u201084M4\u201000008\u201000&pdcontentcomponentid=234176&pdteaserkey=sr1&pditab=allpods&ecomp=6s65kkk&earg=sr1&prid=b009c146\u2010f27f\u20104303\u2010bc5c\u2010f62058ebd084."},{"key":"e_1_2_10_85_1","unstructured":"Natural medicine regulation and legalization SB23\u2010290. [Cited 28 June 2025.] Available from URL:https:\/\/leg.colorado.gov\/bills\/sb23-290."},{"key":"e_1_2_10_86_1","unstructured":"Natural medicine program \u2013 HOME. [Cited 28 June 2025.] Available from URL:https:\/\/dpo.colorado.gov\/NaturalMedicine."},{"key":"e_1_2_10_87_1","unstructured":"Code of Colorado regulations 4 CCR 755\u20101. [Cited 8 Jul 2025.] Available from URL:https:\/\/www.sos.state.co.us\/CCR\/GenerateRulePdf.do?ruleVersionId=11889."},{"key":"e_1_2_10_88_1","unstructured":"Colorado regulated natural medicine rules 1 CCR 213\u20101. [Cited 8 Jul 2025.] Available from URL:https:\/\/www.coloradosos.gov\/CCR\/GenerateRulePdf.do?ruleVersionId=11634&fileName=1%20CCR%20213\u20101."},{"key":"e_1_2_10_89_1","unstructured":"Medical psilocybin program. [Cited 18 June 2025.] Available from URL:https:\/\/www.nmhealth.org\/about\/mcp\/svcs\/mpp\/."},{"key":"e_1_2_10_90_1","unstructured":"BranchLS.Consolidated federal laws of Canada controlled drugs and substances act. 2024. [Cited 26 March 2025.]. Available from URL:https:\/\/laws-lois.justice.gc.ca\/eng\/acts\/C-38.8\/page-11.html#docCont."},{"key":"e_1_2_10_91_1","unstructured":"BranchLS.Consolidated federal laws of Canada controlled drugs and substances act PART VI General (continued). 2024. [Cited 26 March 2025.]. Available from URL:https:\/\/laws-lois.justice.gc.ca\/eng\/acts\/c-38.8\/page-7.html."},{"key":"e_1_2_10_92_1","unstructured":"Health Canada.Psilocybin and psilocin (magic mushrooms). 2012. [Cited 16 February 2025.]. Available from URL:https:\/\/www.canada.ca\/en\/health\u2010canada\/services\/substance\u2010use\/controlled\u2010illegal\u2010drugs\/magic\u2010mushrooms.html."},{"key":"e_1_2_10_93_1","unstructured":"Health Canada.Health Canada's Special Access Programs: Overview. 2004. [Cited 28 June 2025.] Available from URL:https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/special-access.html."},{"key":"e_1_2_10_94_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-66817-0"},{"key":"e_1_2_10_95_1","unstructured":"Government of Canada PWAGSC.Canada gazette part 2 volume 156 number 1: Regulations amending certain regulations relating to restricted drugs (Special Access Program). 2022. [Cited 26 March 2025.] Available from URL:https:\/\/gazette.gc.ca\/rp-pr\/p2\/2022\/2022-01-05\/html\/sor-dors271-eng.html."},{"key":"e_1_2_10_96_1","unstructured":"Health Canada.Special Access Programme \u2013 drugs. 2002. [Cited 26 March 2025.] Available from URL:https:\/\/www.canada.ca\/en\/health\u2010canada\/services\/drugs\u2010health\u2010products\/special\u2010access\/drugs\/special\u2010access\u2010programme\u2010drugs.html."},{"key":"e_1_2_10_97_1","unstructured":"Health Canada.Health Canada's Special Access Programs: request a drug. 2002. [Cited 27 March 2025.] Available from URL:https:\/\/www.canada.ca\/en\/health\u2010canada\/services\/drugs\u2010health\u2010products\/special\u2010access\/drugs.html."},{"key":"e_1_2_10_98_1","unstructured":"Notice to stakeholders: Requests to the Special Access Program (SAP) involving psychedelic\u2010assisted psychotherapy. 2023. [Cited 3 December 2025.] Available from URL:https:\/\/www.canada.ca\/en\/health\u2010canada\/services\/drugs\u2010health\u2010products\/drug\u2010products\/announcements\/requests\u2010special\u2010access\u2010program\u2010psychedelic\u2010assisted\u2010psychotherapy.html."},{"key":"e_1_2_10_99_1","unstructured":"Health Canada.Special Access Program for drugs: Guidance document for industry and practitioners. 2007. [Cited 27 March 2025.] Available from URL:https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/special-access\/drugs\/guidance.html."},{"key":"e_1_2_10_100_1","unstructured":"SR 812.121.11 \u2013 Verordnung des EDI vom 30. Mai 2\u2026 | Fedlex. [Cited 15 June 2025.] Available from URL:https:\/\/www.fedlex.admin.ch\/eli\/cc\/2011\/363\/de."},{"key":"e_1_2_10_101_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00278-024-00711-y"},{"key":"e_1_2_10_102_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12909-025-06871-y"},{"key":"e_1_2_10_103_1","unstructured":"Das Bet\u00e4ubungsmittelgesetz. [Cited 28 June 2025.] Available from URL:https:\/\/www.bag.admin.ch\/de\/das-betaeubungsmittelgesetz."},{"key":"e_1_2_10_104_1","unstructured":"Bundesamt f\u00fcr Gesundheit BAG.Beschr\u00e4nkte medizinische Anwendung von verbotenen Bet\u00e4ubungsmitteln. [Cited 28 June 2025.] Available from URL:https:\/\/www.bag.admin.ch\/de\/beschraenkte-medizinische-anwendung-von-verbotenen-betaeubungsmitteln."},{"key":"e_1_2_10_105_1","unstructured":"Kr\u00e4henmannR Bachmann\u2010HeinzerR Br\u00fchlAet al.Treatment recommendations of the SGPP for the medical treatment of mental illnesses with psychedelics. [Cited 8 Jul 2025.] Available from URL:https:\/\/www.psychiatrie.ch\/fileadmin\/SGPP\/user_upload\/Fachleute\/Empfehlungen\/SGPP\u2010_BE\u2010Psychedelikatherapie_English_Version_18.9.24.pdf."},{"key":"e_1_2_10_106_1","unstructured":"Sn\u011bmovn\u00ed tisk 861. [Cited 8 July 2025.] Available from URL:https:\/\/www.psp.cz\/sqw\/historie.sqw?o=9&T=861."},{"key":"e_1_2_10_107_1","unstructured":"P\u010cR PS od 2021 schv\u00e1len\u00fd text tisku 861. [Cited 8 July 2025.] Available from URL:https:\/\/www.psp.cz\/sqw\/text\/tiskt.sqw?o=9&ct=861&ct1=0&v=PZ&pn=4&pt=1."},{"key":"e_1_2_10_108_1","unstructured":"Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists. Therapeutic Goods Administration (TGA). 2025. [Cited 28 June 2025.] Available from URL:https:\/\/www.tga.gov.au\/news\/media\u2010releases\/change\u2010classification\u2010psilocybin\u2010and\u2010mdma\u2010enable\u2010prescribing\u2010authorised\u2010psychiatrists."},{"key":"e_1_2_10_109_1","unstructured":"Administration (TGA) TG.Re\u2010scheduling of psilocybin and MDMA in the Poisons Standard: Questions and answers. Therapeutic Goods Administration (TGA). 2023. [Cited 21 April 2025.] Available from URL:https:\/\/www.tga.gov.au\/resources\/publication\/scheduling\u2010decisions\u2010final\/notice\u2010final\u2010decision\u2010amend\u2010or\u2010not\u2010amend\u2010current\u2010poisons\u2010standard\u2010june\u20102022\u2010acms\u201038\u2010psilocybine\u2010and\u2010mdma\/re\u2010scheduling\u2010psilocybin\u2010and\u2010mdma\u2010poisons\u2010standard\u2010questions\u2010and\u2010answers."},{"key":"e_1_2_10_110_1","unstructured":"Accessing MDMA (3 4\u2010methylenedioxy\u2010methamphetamine) and psilocybine as a psychiatrist. Therapeutic Goods Administration (TGA). 2025. [Cited 28 June 2025.] Available from URL:https:\/\/www.tga.gov.au\/resources\/guidance\/accessing-mdma-34-methylenedioxy-methamphetamine-and-psilocybine-psychiatrist."},{"key":"e_1_2_10_111_1","unstructured":"Access MDMA or psilocybine (consumers). Therapeutic Goods Administration (TGA). 2025. [Cited 28 June 2025.] Available from URL:https:\/\/www.tga.gov.au\/products\/unapproved\u2010therapeutic\u2010goods\/mdma\u2010and\u2010psilocybine\u2010hub\/access\u2010mdma\u2010or\u2010psilocybine\u2010consumers."},{"key":"e_1_2_10_112_1","unstructured":"Australian Government Department of Health Care A.Authorised prescribers scheme. Australian Government Department of Health and Aged Care. 2025. [Cited 15 June 2025.] Available from URL:https:\/\/www.health.gov.au\/our-work\/authorised-prescribers-scheme."},{"key":"e_1_2_10_113_1","unstructured":"Therapeutic use of MDMA for PTSD and psilocybin for treatment resistant depression. RANZCP. [Cited 15 June 2025.] Available from URL:https:\/\/www.ranzcp.org\/clinical\u2010guidelines\u2010publications\/clinical\u2010guidelines\u2010publications\u2010library\/therapeutic\u2010use\u2010of\u2010mdma\u2010for\u2010ptsd\u2010and\u2010psilocybin\u2010for\u2010treatment\u2010resistant\u2010depression."},{"key":"e_1_2_10_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.funbio.2022.01.003"},{"key":"e_1_2_10_115_1","unstructured":"Clinicaltrials.gov. [Cited 28 June 2025.] Available from URL:https:\/\/clinicaltrials.gov\/."},{"key":"e_1_2_10_116_1","unstructured":"jRCT. [Cited 20 June 2025.] Available from URL:https:\/\/jrct.mhlw.go.jp\/en-latest-detail\/jRCTs031230351."},{"key":"e_1_2_10_117_1","unstructured":"Otsuka Signs Joint Research Agreement with Keio University Industry\u2010academia collaboration for infrastructure development toward the social implementation of psychedelics in Japan. News Releases. Otsuka Pharmaceutical Co. Ltd. [Cited 20 June 2025.] Available from URL:https:\/\/www.otsuka.co.jp\/en\/company\/newsreleases\/2025\/20250508_1.html."},{"key":"e_1_2_10_118_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811241282759"},{"key":"e_1_2_10_119_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2025.1637887"},{"key":"e_1_2_10_120_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1025726"},{"key":"e_1_2_10_121_1","doi-asserted-by":"publisher","DOI":"10.1089\/psymed.2023.0013"},{"key":"e_1_2_10_122_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.20220525"},{"key":"e_1_2_10_123_1","first-page":"211","article-title":"Whitewashing psychedelics: Racial equity in the emerging field of psychedelic\u2010assisted mental health research and treatment","volume":"28","author":"Thrul J","year":"2021","journal-title":"Drugs (Abingdon Engl.)"},{"key":"e_1_2_10_124_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.0442"},{"key":"e_1_2_10_125_1","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.16017"}],"container-title":["Psychiatry and Clinical Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pcn.70042","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/pcn.70042","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pcn.70042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:44:08Z","timestamp":1780919048000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pcn.70042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":124,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1111\/pcn.70042"],"URL":"https:\/\/doi.org\/10.1111\/pcn.70042","archive":["Portico"],"relation":{},"ISSN":["1323-1316","1440-1819"],"issn-type":[{"value":"1323-1316","type":"print"},{"value":"1440-1819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"2025-07-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}